AD_____

Award Number: DAMD17-02-1-0535

TITLE: Roles of Osteonecti in Breast Cancer Metastasis to Bone

PRINCIPAL INVESTIGATOR: Dianalee A. Campo

CONTRACTING ORGANIZATION: The Pennsylvania State University University Park, Pennsylvania 16802-7000

REPORT DATE: May 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040917 083

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188		
Public reporting burden for this collection of info the data needed, and completing and reviewing	prmation is estimated to average 1 hour per response this collection of information. Send comments regar	, including the time for reviewing in ding this burden estimate or any ot	structions, searching exi her aspect of this collect	sting data sources, gathering and maintaining of information, including suggestions for	
Anagement and Budget, Paperwork Reductio	ers Services, Directorate for Information Operations a n Project (0704-0188), Washington, DC 20503	Ind Reports, 1215 Jefferson Davis I	Highway, Suite 1204, Arl	lington, VA 22202-4302, and to the Office c	
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND	DATES COVERED		
	May 2004	Ainitial Sullillary		103 - 14 Api 2004)	
Roles of Osteonectin	in Breast Cancer Metast	asis in Bone	DAMD17-02-	-02-1-0535	
6. AUTHOR(S)			-		
Dianalee A. Campo					
7. PERFORMING ORGANIZATION	. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERF			FORMING ORGANIZATION	
The Pennsylvania State University University Park, Pennsylvania 16802-7000			REPORT NUMBER		
<i>E-Mail:</i> dac234@psu.edu					
9. SPONSORING / MONITORING			10. SPONSORING / MONITORING		
AGENCY NAME(S) AND ADD	GENCY NAME(S) AND ADDRESS(ES) AGENCY F			EPORT NUMBER	
U.S. Army Medical Res	S. Army Medical Research and Materiel Command				
	.d 21702-5012				
Fort Detrick, Marylan					
Fort Detrick, Marylan <i>11. SUPPLEMENTARY NOTES</i>			<u></u>		
Fort Detrick, Marylan 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABIL Approved for Public R	<i>ITY STATEMENT</i> elease; Distribution Un	limited	I	12b. DISTRIBUTION CODE	
Fort Detrick, Marylan 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABIL Approved for Public R 13. ABSTRACT (Maximum 200 V Osteonectin is a secre	ITY STATEMENT Lelease; Distribution Un Vords/	limited	functions	12b. DISTRIBUTION CODE	
Fort Detrick, Marylan 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABIL Approved for Public R 13. ABSTRACT (Maximum 200 V Osteonectin is a secre adhesion modulation ar breast cancer cells de Other studies demonstr endothelial cell layer hypothesize that there osteonectin, and vascu SDS-PAGE under reducir variance in molecular Results suggest that k configurations of disu pattern of disulfide I phosphorylation assays detected by interferer has supported the hypo secreted and vascular, 14. SUBJECT TERMS	<i>ITY STATEMENT</i> elease; Distribution Un <i>Vords)</i> eted matrix protein that I ad chemoattraction. It has espite the evidence that a cate the ability of osteon c even though some endother e are differences between alar endothelial-derived on and non-reducing condi- size between osteonectin preast cancer cells secre- ulfide linkages, whereas I links. No differences we s while osteonectin-induc- nce reflection microscopy othesis that there are stated bone-secreted osteonectin	limited has a variety of as been implicate some cancer cells hectin to permeab elial cells also cancer-derived co osteonectin. Ost tions followed by from different s te two types of co cone cells secret re observed from ed endothelial pe . The research co ructural different h.	functions, d as a chem secrete os pilize a vas secrete ost osteonectin, conectin wa immunoblot cources is d osteonectin deglycosyla ermeabilizti completed in aces between	12b. DISTRIBUTION CODE including cell oattractant for teonectin. cular eonectin. We bone-derived s separated by ting; a small etected. with different in with a single tion and on was also not the last year breast cancer-	
Fort Detrick, Marylan 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABIL Approved for Public R 13. ABSTRACT (Maximum 200 V Osteonectin is a secre adhesion modulation ar breast cancer cells de Other studies demonstr endothelial cell layer hypothesize that there osteonectin, and vascu SDS-PAGE under reducir variance in molecular Results suggest that k configurations of disu pattern of disulfide I phosphorylation assays detected by interferer has supported the hypo secreted and vascular, 14. SUBJECT TERMS Bone-derived chemotac	<i>Vords)</i> eted matrix protein that I de chemoattraction. It has espite the evidence that a cate the ability of osteon c even though some endothe e are differences between alar endothelial-derived of size between osteonectin preast cancer cells secret alfide linkages, whereas I links. No differences we s while osteonectin-induce the reflection microscopy othesis that there are st /bone-secreted osteonectin	limited has a variety of as been implicate some cancer cells hectin to permeab elial cells also cancer-derived of osteonectin. Ost tions followed by from different s te two types of of cone cells secret re observed from ed endothelial pe . The research of ructural different h.	functions, d as a chem secrete os ilize a vas secrete ost steonectin, conectin wa immunoblot cources is d steonectin e osteonect deglycosyla ermeabilizti completed in aces between	12b. DISTRIBUTION CODE including cell oattractant for teonectin. cular eonectin. We bone-derived s separated by ting; a small etected. with different in with a single tion and on was also not the last year breast cancer-	
Fort Detrick, Marylan 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABIL Approved for Public R 13. ABSTRACT (Maximum 200 V Osteonectin is a secre adhesion modulation ar breast cancer cells de Other studies demonstr endothelial cell layer hypothesize that there osteonectin, and vascu SDS-PAGE under reducir variance in molecular Results suggest that k configurations of disu pattern of disulfide I phosphorylation assays detected by interferer has supported the hypo secreted and vascular, 14. SUBJECT TERMS Bone-derived chemotace migration, cell cultur	<i>ITY STATEMENT</i> elease; Distribution Un <i>Vords)</i> eted matrix protein that I ad chemoattraction. It has espite the evidence that a cate the ability of osteon c even though some endother e are differences between alar endothelial-derived on and non-reducing condi- size between osteonectin breast cancer cells secre- ulfide linkages, whereas I links. No differences we s while osteonectin-induce the reflection microscopy othesis that there are st /bone-secreted osteonectin etic factors, vasculatur are model system, cell-c	limited has a variety of as been implicate some cancer cells hectin to permeab elial cells also cancer-derived co osteonectin. Ost tions followed by from different s te two types of co cone cells secret re observed from ed endothelial pe . The research co ructural different h. e of bone, cell ell interactions	functions, d as a chem secrete os pilize a vas secrete ost osteonectin, eonectin wa immunoblot cources is d osteonectin deglycosyla ermeabilizti completed in aces between	12b. DISTRIBUTION CODE including cell oattractant for teonectin. cular eonectin. We bone-derived s separated by ting; a small etected. with different in with a single tion and on was also not the last year breast cancer- 15. NUMBER OF PAGES 8 16. PRICE CODE	
Fort Detrick, Marylan 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABIL Approved for Public R 13. ABSTRACT (Maximum 200 V Osteonectin is a secre adhesion modulation ar breast cancer cells de Other studies demonstr endothelial cell layer hypothesize that there osteonectin, and vascu SDS-PAGE under reducir variance in molecular Results suggest that k configurations of disu pattern of disulfide I phosphorylation assays detected by interferer has supported the hypo secreted and vascular, 14. SUBJECT TERMS Bone-derived chemotac migration, cell cultur	Vords) eted matrix protein that I deted matrix protein that I and chemoattraction. It has espite the evidence that a cate the ability of osteon c even though some endothed are differences between alar endothelial-derived on and non-reducing condi- size between osteonectin breast cancer cells secre- alfide linkages, whereas I links. No differences we s while osteonectin-induced the state there are state (bone-secreted osteonectin- ettic factors, vasculatured are model system, cell-c	limited has a variety of as been implicate some cancer cells hectin to permeab elial cells also cancer-derived of osteonectin. Ost tions followed by from different s te two types of of cone cells secret re observed from ed endothelial pe . The research of ructural different h.	functions, d as a chem secrete os ilize a vas secrete ost steonectin, conectin wa immunoblot cources is d osteonectin deglycosyla ermeabilizti completed in aces between	12b. DISTRIBUTION CODE including cell oattractant for teonectin. cular eonectin. We bone-derived s separated by ting; a small etected. with different in with a single tion and on was also not the last year breast cancer- 15. NUMBER OF PAGES 8 16. PRICE CODE	
Fort Detrick, Marylan 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABIL Approved for Public R 13. ABSTRACT (Maximum 200 V Osteonectin is a secred adhesion modulation ar breast cancer cells de Other studies demonstring endothelial cell layer hypothesize that there osteonectin, and vascu SDS-PAGE under reducin variance in molecular Results suggest that k configurations of disu pattern of disulfide I phosphorylation assays detected by interferer has supported the hypothesize basereted and vascular, 14. SUBJECT TERMS Bone-derived chemotacomigration, cell cultur 17. SECURITY CLASSIFICATION OF REPORT	Vords) eted matrix protein that I deted matrix protein that I and chemoattraction. It has espite the evidence that a cate the ability of osteon cate the ability of	limited has a variety of as been implicate some cancer cells hectin to permeab elial cells also cancer-derived of osteonectin. Ost tions followed by from different s te two types of of cone cells secret re observed from ed endothelial pe . The research of ructural different h. e of bone, cell ell interactions 19. SECURITY CLASSI OF ABSTRACT	functions, d as a chem secrete os ilize a vas secrete ost secrete ost secrete ost osteonectin wa immunoblot cources is d seconectin deglycosyla ermeabilizti completed in aces between	12b. DISTRIBUTION CODE including cell oattractant for teonectin. cular eonectin. We bone-derived s separated by ting; a small etected. with different in with a single tion and on was also not the last year breast cancer- 15. NUMBER OF PAGES 8 16. PRICE CODE 20. LIMITATION OF ABSTRAC	

Table of Contents

(

•

.

Cover1
SF 2982
Table of Contents3
Introduction4
Body4
Key Research Accomplishments7
Reportable Outcomes7
Conclusions7
References8
Appendices

Introduction

Osteonectin is a secreted matrix protein that has a variety of functions, including cell adhesion modulation and chemoattraction. It has been implicated as a chemoattractant for breast cancer cells despite the evidence that some cancer cells secrete osteonectin. Other studies demonstrate the ability of osteonectin to permeabilize the vascular endothelial cell layer even though some endothelial cells also secrete osteonectin. This research aims to examine the differences between cancer-derived osteonectin, bonederived osteonectin, and vascular endothelial-derived osteonectin. Of key interest is that these differences may contribute to the affinity of breast cancer cells to bone. During the past year of research, structural and functional differences between the two types of osteonectin have been analyzed.

Body

Task 1 involves analysis of structural differences between osteonectin of different sources. We separated osteonectin by SDS-PAGE under reducing conditions followed by immunoblotting; a small variance in molecular size between osteonectin from different sources is detected. Two bands from the MDA-MB-435 (~41 and 38 kDa) and MDA-MB-468 (~41 and 36 kDA) cell lines under non-reducing conditions (previously reported) appear as a single band (~57 and 54 kDa, respectively) when reduced; this phenomenon is not observed in the bone (hFOB1.19) or endothelial-derived (HBME-1) osteonectin which display a only a single band under both reducing (~53 kDa) and non-reducing (~38kDa) conditions (Figure 1). These results suggest that breast cancer cells secrete two types of osteonectin with different configurations of disulfide linkages, whereas bone cells secrete osteonectin with a single pattern of disulfide links. Because disulfide bonds influence protein folding, at least one of the breast cancer-secreted types of osteonectin.



Figure 1. Comparison of molecular sizes of osteonectin from breast cancer cells and bone cells by immunoblotting. Conditioned serum-replacement medium (Sigma) was collected after 48 hours and separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose and then immunoblotted. Osteonectin from MDA-MB-435

cells is \sim 57 kDa while MDA-MB-468 is \sim 54 kDa. Osteonectin from HBME-1 and hFOB cell lines was \sim 53 kDa..

Task 1A and 1B have now been completed and were reported mainly last year. Task 1C, investigation of glycosylation differences between breast cancer-derived and bonederived osteonectin, was further analyzed by use of an enzymatic deglycosylation assay. Contrary to previous results using a different assay system which included the presence of tunicamycin, all sources of osteonectin have similar levels of glycosylation. The osteonectin from HBME-1, hFOB, MDA-MB-435, and MDA-MB-468 cell lines lack sialic acid and seronine/threonine linked glycosyl groups. All tested cell lines produced osteonectin with N-linked glycosylation (Figure 2). These results contradict last year's finding that the breast cancer cell line-derived osteonectin lack N-linked glycosylation as determined by tunicamycin assays. Further examinations led to the finding that the tested breast cancer cell lines are resistant to tunicamycin resulting in inaccurate data.



Figure 2. Comparison of molecular size of deglycosylated osteonectin. Osteonectin from all cell types have N-linked glycosylation while sialic acid and Ser/Thr-linked glycosylation are absent. Affinity purified osteonectin was treated with an enzymatic deglycosylation kit (Sigma), separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted.

Literature suggests that osteonectin has multiple serine sites for possible phosphorylation (Fisher et al., 1987); therefore analysis of phosphoserines has been conducted to support Task 1. Osteonectin was purified by an affinity column, transferred to nitrocellulose and immunoblotted for phosphorylated serine. Preliminary data suggests that none of the collected osteonectin from HBME-1, hFOB, or the breast cancer cell lines contain phosphorylated serine groups.

Task 1D, test osteonectin for affinity to other matrix proteins, is presently being conducted. The initial tests have included osteonectin binding to collagen type I, collagen type IV and fibronectin. Future assays will be done on Nunc Maxisorb 96-well plates; our laboratory has purchased a plate washer that will result in more accurate and consistent data.

In preliminary research for Task 2, we have been unable to replicate assays showing permeablilization of an endothelial layer due to the presence of osteonectin. Interference reflection microscopy on an HBME-1 cell layer treated with 1μ g/ml of MDA-MB-435-derived osteonectin failed to show any changes in cell shape, permeablilization or loss of focal adhesion complexes (Figure 3). The study indicates that breast cancer-derived osteonectin does not influence vascular endothelial cell adhesion. Immunocytochemistry for actin redistribution and loss of focal adhesion complexes (through loss of vinculin or talin) need to be conducted.



Figure 3. Comparison of focal adhesion complexes in the presence and absence of osteonectin. After an hour with $+/-1 \mu g/ml MDA-MB-435$ osteonectin treatment, the number of focal adhesions in HBME-1 cells did not change. Glass cover slides are coated with $20\mu g/ml$ fibronectin (Biomedical Technologies Inc., Stoughton, MA).

HBME-1 cells were grown to confluence, treated with either 0 or 1 \mu g/ml MDA-MB-435 osteonectin.

Key Research Accomplishments

- 1. Determined differences in disulfide linkage patterns between osteonectin from breast cancer cells compared to osteonectin of bone or vascular endothelial cells.
- 2. Osteonectin from breast cancer, osteoblasts and vascular endothelial cells do not have sialic acid or Ser/Thr linked glycolyl groups.
- 3. Osteonectin from breast cancer, osteoblasts and vascular endothelial cells have Nlinked glycosyl groups.
- 4. Preliminary data suggests that osteonectin from HBME-1, hFOB or two breast cancer cell lines do not contain phosphorylated serine sites.
- 5. Loss of focal adhesion plaques or induced endothelial permeabilization due to the presence of bone-derived osteonectin was not detected by interference reflection microscopy.

Reportable Outcomes

Activities supported by this award this year included finishing all of my course requirements for completion of my degree. Also, in August of 2003 I passed the comprehensive exam. I participated in a weekly journal club in which current literature on breast cancer, bone-related knock-out discoveries, and cell communication was presented and discussed by faculty and other graduate students. Each semester I attend, typically on a weekly basis, on-campus seminars dealing with a variety of disciplines such as neurobiology, cancer, developmental biology, cell biology, nutrition, and careers in science. I participated in the "American Association of Cancer Research" meeting in Washington D.C, the "Fourth North America Symposium on Skeletal Complications of Malignancy" in San Antonio Texas, and the "Women in the Sciences and Engineering VOICES" conference in State College Pennsylvania; this gave me the opportunity to meet and interact with other scientists in the fields of cancer and bone. In the laboratory, I have mastered many new techniques including ELISA development for the substrate binding assays, protein analysis by immunoblotting and enzymatic treatments, confocal microscopy, and interference reflection microscopy.

Conclusion

The research completed in the second year supports the hypothesis that there are structural differences between breast cancer-secreted and bone-secreted osteonectin. This has been demonstrated by size analysis on western blots and the conclusion that different arrangements of disulfide linkages exist. Because disulfide bonds influence protein folding, at least one of the breast cancer-secreted types of osteonectin will have a different three-dimensional structure from the bone or endothelial-derived osteonectin. The past year of research will further identify structural variation and better understand the effects osteonectin has on living cells.

References

J

Fisher LW, Hawkins GR, Tuross N, Termine JD. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem. 262 (20): p 9702-9708, 1987.